Introduction Many treatment regimens have been evaluated in transplant-ineligible (TIE)
patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to …

This study aims to evaluate the efficacy and safety of Daratumumab-based induction therapy
(DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs including …

Background Despite major therapeutic advances, the rational choice of the most appropriate
first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is …

The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients
(NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or …

Aims To assess the real-world healthcare resource utilization (HRU) and costs associated
with different proteasome inhibitors (PIs) for the treatment of patients with relapsed and/or …

Purpose Multiple myeloma is still an incurable disease In the past decade, with the
continuous progress of treatment methods, the progression-free survival of patients has …

Objectives To present an overview of evidence of efficacy, safety, and health-related quality
of life of lenalidomide or thalidomide for transplant-ineligible multiple myeloma. Methods A …

ABSTRACT Introduction Monoclonal antibodies (MoAbs) are rapidly changing the
therapeutic scenario of multiple myeloma. Most of the available data, however, come from …

Objective To systematically evaluate the efficacy and safety of combination regimens
containing daratumumab in patients with multiple myeloma (MM). Methods A systematic …

Introduction: Randomized clinical trials showed that bortezomib, in addition to conventional
chemotherapy, improves survival and disease progression in multiple myeloma (MM) …